trenibotulinumtoxinE clinical trials
Also written AGN-151586.
How each study uses trenibotulinumtoxinE is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 15 Jul 2026 · Boey · EMEA/H/C/006420 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AGN-151586
- 10
Studies by the year they started
10 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test trenibotulinumtoxinE.
Studies
Open first, then newest update. How each study uses trenibotulinumtoxinE is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesActive, not recruitingPhase 1AbbVieNCT07756580Written as AGN-151586
- A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsActive, not recruitingPhase 2AbbVieNCT07730554Written as AGN-151586
- A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesCompletedPhase 3AbbVieNCT05248893Written as AGN-151586
- A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar LinesCompletedPhase 1AbbVieNCT05496335Written as AGN-151586
- Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar LinesCompletedPhase 1AbbVieNCT06151561Written as AGN-151586
- A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar LinesCompletedPhase 3AbbVieNCT06308198Written as AGN-151586
- A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar LinesCompletedPhase 3AbbVieNCT05248880Written as AGN-151586
- A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)CompletedPhase 1AbbVieNCT06834789Written as AGN-151586
- A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar LinesCompletedPhase 3AbbVieNCT05248867Written as AGN-151586
- AGN-151586 Dose-Ranging Study for Treatment of Glabellar LinesCompletedPhase 2AllerganNCT04096326Written as AGN-151586